Trial Profile
A study evaluating distribution and extent of tau pathology in Alzheimer's disease and progressive supranuclear palsy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2017
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment; Progressive supranuclear palsy
- Focus Diagnostic use
- 15 Jun 2017 New trial record